2020
Medical marijuana certification for patients with sickle cell disease: a report of a single center experience
Curtis SA, Lew D, Spodick J, Hendrickson JE, Minniti CP, Roberts JD. Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances 2020, 4: 3814-3821. PMID: 32790846, PMCID: PMC7448584, DOI: 10.1182/bloodadvances.2020002325.Peer-Reviewed Original ResearchConceptsOpioid useMedical marijuanaSickle cell disease (SCD) reportBaseline opioid useSingle-center experienceHealth care utilizationSickle cell diseaseOpioid utilizationClinical characteristicsMost patientsCenter experienceCare utilizationSCD patientsInpatient hospitalizationRandom patientsAdmission ratesCell diseasePatientsRetrospective dataDisease reportsStudy periodHealth careCannabis productsCannabisEdible cannabis products
2019
Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types
Curtis S, Forray A, Hendrickson J, Roberts J. Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types. Blood 2019, 134: 1028. DOI: 10.1182/blood-2019-129106.Peer-Reviewed Original ResearchSickle cell diseaseNeuropathic pain qualitiesNeuropathic painNociceptive painPain impactBaseline painED usePain qualityWorse sleepOpioid usePain groupChronic painCell diseaseEpisode frequencyOutcomes Measurement Information System (PROMIS) domainsAdult Sickle Cell QualityAverage daily opioid useHigher C-reactive proteinYale-New Haven HospitalHigh ED useWorse clinical outcomesC-reactive proteinDaily opioid useEmergency department useHalf of adults
2018
Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell Center
Curtis S, Lew D, Spodick J, Roberts J. Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell Center. Blood 2018, 132: 858. DOI: 10.1182/blood-2018-99-118290.Peer-Reviewed Original ResearchSickle cell diseaseAcute service utilizationOral morphine equivalentsPrevious marijuana useOpioid useDaily opioid useService utilizationHospital admissionAdmission ratesHydroxyurea useChronic painInsurance typeAcute servicesCell diseaseAcute care service utilizationTotal oral morphine equivalentsBaseline opioid useRegular clinic visitsPrescription monitoring programsMarijuana useSickle Cell CenterOnly clinical differenceQuality of lifeT-testElectronic medical recordsMedical Marijuana Certification for Patients with Sickle Cell Disease: A Survey Study of Patient's Use and Preferences
Curtis S, Spodick J, Lew D, Roberts J. Medical Marijuana Certification for Patients with Sickle Cell Disease: A Survey Study of Patient's Use and Preferences. Blood 2018, 132: 1094. DOI: 10.1182/blood-2018-99-118345.Peer-Reviewed Original ResearchMedical marijuanaOpioid useExact testSickle cell disease clinicMarijuana usePain medication useLess pain medicationEfficacy of marijuanaSickle cell diseaseFisher's exact testImproved safety profileMedical marijuana certificationSCD clinicPain medicationAdult patientsClinic visitsDisease clinicMedication useSymptom managementLess painSafety profileLung toxicityCell diseaseOpiate usePatients
2015
Daily home opioid use in adults with sickle cell disease: The PiSCES project.
Smith WR, McClish DK, Dahman BA, Levenson JL, Aisiku IP, de A Citero V, Bovbjerg VE, Roberts JD, Penberthy LT, Roseff SD. Daily home opioid use in adults with sickle cell disease: The PiSCES project. Journal Of Opioid Management 2015, 11: 243-53. PMID: 25985809, DOI: 10.5055/jom.2015.0273.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdaptation, PsychologicalAdolescentAdultAnalgesics, OpioidAnemia, Sickle CellAntisickling AgentsCost of IllnessDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansHydroxyureaLongitudinal StudiesMaleMiddle AgedPainPain MeasurementQuality of LifeSelf AdministrationTime FactorsTreatment OutcomeYoung AdultConceptsSickle cell diseaseHome opioid useOpioid usePain daysOpioid usersMean painCell diseasePsychosocial variablesDaily pain diaryMajority of patientsNon-opioid analgesicsSomatic symptom burdenPiSCES projectOpioid prescribingPain frequencyCohort studySymptom burdenPain diaryPain intensityPatient characteristicsPhysical QoLOpioidsPatientsSCD samplesSimilar association
2012
Pain and disease severity relate to long versus short-acting opioid use in adults with sickle cell disease: the PiSCES project
Smith W, McClish D, Dahman B, Levenson J, Aisiku I, Citero V, Bovbjerg V, Roberts J, Penberthy L, Roseff S, Scherer M, Weaver M. Pain and disease severity relate to long versus short-acting opioid use in adults with sickle cell disease: the PiSCES project. Journal Of Pain 2012, 13: s15. DOI: 10.1016/j.jpain.2012.01.067.Peer-Reviewed Original ResearchHome opioid use in sickle cell disease and relationship to pain and psychosocial variables: the PiSCES project
Smith W, McClish D, Dahman B, Levenson J, Aisiku I, Citero V, Bovbjerg V, Roberts J, Penberthy L, Roseff S, Scherer M, Weaver M. Home opioid use in sickle cell disease and relationship to pain and psychosocial variables: the PiSCES project. Journal Of Pain 2012, 13: s13. DOI: 10.1016/j.jpain.2012.01.060.Peer-Reviewed Original Research